Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study
Andrew J. Wagner, William D. Tap, Sebastian Bauer, Jean Yves Blay, Jayesh Desai, Hans Gelderblom, Emanuela Palmerini, Christopher W. Ryan, Charles Peterfy, John H. Healey, Michiel A. J. van de Sande, Meng Qian, Dale E. Shuster, Abdul Waheed Rajper, Xin Ye, Kristen M. Tecson, Margaret Wooddell, Silvia Stacchiotti (2025). Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN study. , 30(7), DOI: https://doi.org/10.1093/oncolo/oyae345.
Article23 days agoPredictive gene signature for the efficacy of pazopanib in solitary fibrous tumor: A Spanish Group for Research in Sarcoma (GEIS) study.
David S. Moura, Jesús M. López Martí, Silvia Stacchiotti, Ana Sebio, Andrés Redondo, Nicolas Penel, Jean Yves Blay, Xavier García del Muro, Giovanni Grignani, Josefina Cruz Jurado, Javier Martínez‐Trufero, Antoine Italiano, Emanuela Palmerini, Daniel Bernabéu, José L. Mondaza-Hernández, Nadia Hindi, Javier Martín‐Broto (2025). Predictive gene signature for the efficacy of pazopanib in solitary fibrous tumor: A Spanish Group for Research in Sarcoma (GEIS) study.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.11540.
Article23 days ago151TiP TANGENT: A phase III, global, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor
Emanuela Palmerini, S. Veltkamp, H. Gelderblom, Javier Martín‐Broto, A. Sebio García, M. Van de Sande, Gabriel Tinoco, Elyse Seltzer, Matthew Davies, Jean Yves Blay (2025). 151TiP TANGENT: A phase III, global, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor. , 10, DOI: https://doi.org/10.1016/j.esmoop.2025.104464.
Article23 days agoA phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).
Hans Gelderblom, Emanuela Palmerini, Jean Yves Blay, Michiel A. J. van de Sande, Javier Martín‐Broto, Raúl Terés, M. B. Davies, Elyse Seltzer, S. Veltkamp, Gabriel Tinoco (2025). A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor (TANGENT).. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.tps11584.
Article23 days agoRedefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial
Andrea Vanzulli, R. Vigorito, Ciriaco Buonomenna, Emanuela Palmerini, Vittorio Quagliuolo, Giovanni Grignani, Antonella Brunello, Jean Yves Blay, Roberto Díaz Beveridge, Virginia Ferraresi, Iwona Ługowska, Sara Pizzamiglio, Paolo Verderio, V. Duroni, Valeria Fontana, D.M. Donati, Elena Palassini, Giuseppe Bianchi, Alexia Bertuzzi, Angela Buonadonna, Sandro Pasquali, Angelo Paolo Dei Tos, Paolo G. Casali, Carlo Morosi, Silvia Stacchiotti, Alessandro Gronchi (2025). Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial. , 10(3), DOI: https://doi.org/10.1016/j.esmoop.2025.104299.
Article23 days ago